Kenvue Inc. (NYSE:KVUE) Shares Acquired by Financial Advocates Investment Management

Financial Advocates Investment Management lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 208.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 38,113 shares of the company’s stock after purchasing an additional 25,752 shares during the quarter. Financial Advocates Investment Management’s holdings in Kenvue were worth $814,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp raised its stake in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares in the last quarter. Holocene Advisors LP raised its position in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after acquiring an additional 5,975,392 shares during the last quarter. M&G PLC lifted its holdings in shares of Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after purchasing an additional 3,660,730 shares in the last quarter. Finally, FMR LLC grew its position in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $20.23 on Friday. The stock has a 50-day simple moving average of $21.61 and a 200-day simple moving average of $21.93. The firm has a market cap of $38.79 billion, a P/E ratio of 36.78, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. On average, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

A number of brokerages have commented on KVUE. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Canaccord Genuity Group decreased their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.